Updated on 19 June 2012
The Indian pharmaceutical industry witnessed 13 outbound deals in 2011. Some of the deals include acquisition of Diasis Diagnostic Systems by Transasia Bio-Medicals; acquisition of WCI consulting group by TAKE Solutions; acquisition of Bremer Pharma GmbH by Cadila Healthcare; acquisition of Neshar Pharmaceuticals; acquisition of two generic drugs by Zydus Pharmaceuticals, which is a subsidiary of Cadila Healthcare; acquisition of Goanna from Aspen Pharmacare by Lupin, acquisition of Onyx Research Chemicals by IPCA Labs for $7.39 million; acquisition of Uquifa SA by Vivimed Labs for $ 55 million; and acquisition of Irom Pharmaceutical by Lupin .
There were around 15 inbound deals in India. Major deals included acquisition of Nutritional business of Wockhardt by Danone for $355 million; Russian brands of J B Chemicals by Cilag GmbH for $260 million; acquisition of certain assets of Kilitch Drugs India by Akom for $43.48 million; acquisition of Edict Pharmaceuticals by Par Pharmaceutical Companies for $36.7 million; acquisition of Unimark Remedies by Hikma Pharmaceuticals for $33.3 million; acquisition of Bioserve Clinical Research by QPS Holdings; and acquisition of Aurobindo (Datong) BioPharma, a Chinese subsidiary of Aurobindo Pharma by Sinopharm -China National Pharmaceutical Group Corporation. M&A activity will continue to happen in India in all areas such as inbound, outbound and domestic deals. These activities will play a major role in the growth of the companies in particular and the industry in general.